Lilly's Retatrutide Cuts Weight Up to 25% in Trials

Newly published phase 3 results show Eli Lilly's triple-hormone drug retatrutide cut body weight by up to 25% in obesity and nearly 21% in type 2 diabetes.

@sharedot

Lilly's Retatrutide Cuts Weight Up to 25% in Trials

By @sharedot · · 8 pages

  • Health
  • Obesity
  • Diabetes
  • Pharmaceuticals

Newly published phase 3 results show Eli Lilly's triple-hormone drug retatrutide cut body weight by up to 25% in obesity and nearly 21% in type 2 diabetes.

What Happened

Eli Lilly's experimental obesity drug retatrutide delivered its long-awaited late-stage results on September 29, 2026, published in the New England Journal of Medicine.

In the obesity trial, patients on the highest 12 mg dose lost an average of 25 percent of their body weight after 80 weeks, rising to an average of 30 percent after an extension to 104 weeks, and more than a third of participants on the drug lost 30 percent or more of their starting weight.

The same day, findings from the parallel TRIUMPH-2 diabetes trial appeared in The Lancet.

Why It's Surprising

No approved obesity medication has produced weight loss of this magnitude, which is why the drug had already drawn gray-market demand before approval.

Equally striking is the diabetes population result: According to Everyday Health, people with type 2 diabetes have historically lost less weight on obesity medications than people without diabetes, yet TRIUMPH-2 participants lost an average of nearly 21 percent of their body weight at 80 weeks.

Vanderbilt obesity specialist Dr. Gitanjali Srivastava called the results impressive precisely because of that population, noting the drug 'treats the disease that drives the diabetes and the diabetes itself.'

The Evidence

The obesity trial enrolled 2,339 participants across 131 sites in 11 countries, randomized to 4 mg, 9 mg, or 12 mg of retatrutide or a placebo; average starting weight was about 113 kg with a BMI of 40, according to Ars Technica.

The diabetes trial, per Everyday Health, followed roughly 1,200 adults with type 2 diabetes and overweight or obesity: average weight loss was 11.9 percent at 4 mg, 16.8 percent at 9 mg, and 18.8 percent at 12 mg versus 5.1 percent on placebo, with A1C drops of about 1.4 to 1.5 points and 72 percent reaching an A1C of 6.5 percent or lower.

Beyond the Scale

Retatrutide is a 'triple G' agonist, a single synthetic peptide acting on the GLP-1, GIP, and glucagon receptors — one more hormone target than tirzepatide's two and semaglutide's one, and the interplay of the three hormones spans blood sugar regulation, fullness, and lipid processing.

The obesity trial also found knee pain fell by up to 62 percent in participants with obesity-linked knee osteoarthritis, sleep apnea events dropped by up to 57 percent, blood pressure, triglycerides, and LDL cholesterol improved, and prediabetes resolved in more than 90 percent of participants who had it at the start, Ars Technica reports.

The Caveats

The drug remains experimental and is not FDA-approved. A notable limitation, as Ars Technica notes, is that the trial did not compare retatrutide head-to-head against an existing treatment such as tirzepatide, so its relative standing is unproven.

Safety so far resembles existing GLP-1 drugs — mainly transient mild-to-moderate gastrointestinal symptoms — though some participants reported dizziness and low blood pressure, and the trial was too small to assess rarer risks: ten cardiovascular events and ten pancreatitis reports were recorded.

Experts are also warning against bootleg 'research use' retatrutide sold online, which pharmacist Christine Bonarrigo of Tufts Medical Center told Everyday Health is not necessarily the product studied in trials.

What Comes Next

The phase 3 publications put retatrutide one step closer to an FDA decision, with Everyday Health noting the results move the medication toward a possible approval.

If cleared, specialists expect it to be most valuable for patients with obesity who need substantial weight loss to address serious complications such as type 2 diabetes, fatty liver disease, sleep apnea, or joint disease, and for those who have not responded well to current medications or are not candidates for bariatric surgery.

Meanwhile, clinicians urge patients to stick with approved obesity drugs rather than gamble on unregulated vials, since the potent drug's effects should be monitored by a clinician.

Sources

  1. arstechnica.com › Most powerful obesity drug yet: People lost up to 25% of weight in trial
  2. everydayhealth.com › Retatrutide Led to Significant Weight Loss in Newly Published Diabetes Trial
  3. wtvbam.com › Lilly's experimental drug cuts weight by 21% in diabetes trial

More on Health